{
  "id": 12517556,
  "title": "HLB’s Lirafugratinib Advances to European Review After U.S. Approval",
  "url": "https://urgent.news/2026/10/07/hlbs-lirafugratinib-advances-to-european-review-after-u-s-approval",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-07T01:58:18.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=278336"
  },
  "original_language": "en",
  "account": null,
  "summary": "Following its U.S. approval, HLB’s cholangiocarcinoma drug lirafugratinib has entered formal regulatory review for European market entry. About two weeks after receiving approval from the U.S. Food and Drug Administration (FDA), the drug has moved into the formal marketing authorization review proce",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}